Table 2 Demographic, laboratory and clinical characterstics of HIV patients on HAART in Adigrat General Hospital, Eastern Tigrai, Ethiopia; 2019: A retrospective follow up (n = 393)
Variables | Category | Frequency, N [%] | TB status of HIV patients | |
|---|---|---|---|---|
Negative, N [%] | Positive, N [%] | |||
Sex | Male | 131 [33.3] | 87 [66.4] | 44 [33.6] |
Female | 262 [66.7] | 183 [69.8] | 79 [30.2] | |
Age category | <  15 years | 22 [5.6] | 16 [72.7] | 06 [27.3] |
15–30 years | 48 [12.2] | 38 [79.2] | 10 [20.8] | |
31–45 years | 205 [52.2] | 131 [63.9] | 74 [36.1] | |
46–60 years | 106 [27] | 77 [72.6] | 29 [27.4] | |
>  60 years | 12 [3.1] | 08 [66.7] | 04 [33.3] | |
Residence | Urban | 249 [63.4] | 168 [67.5] | 81 [32.5] |
Rural | 144 [36.6] | 102 [70.8] | 42 [29.2] | |
BMI | Normal | 224 [57] | 155 [69.2] | 69 [30.8] |
Overweight | 37 [9.4] | 32 [86.5] | 05 [13.5] | |
Undernourished | 132 [33.6] | 83 [62.9] | 49 [37.1] | |
Cotrimoxazole intake | No | 80 [20.4] | 53 [66.3] | 27 [33.7] |
Yes | 313 [79.6] | 217 [69.3] | 96 [29.7] | |
Eligibility criteria | Clinical staging | 314 [79.9] | 222 [70.7] | 92 [29.3] |
Test and treat | 24 [6.1] | 13 [54.2] | 11 [45.8] | |
Transferred in | 55 [14] | 35 [63.6] | 20 [36.4] | |
Functional status | Working | 364 [92.6] | 246 [67.6] | 118 [32.4] |
Ambulatory | 26 [6.6] | 23 [88.5] | 03 [11.5] | |
Bedridden | 3 [0.8] | 01 [33.3] | 02 [66.7] | |
WHO stage | Stage I | 350 [89.1] | 243 [69.4] | 107 [30.6] |
Stage II | 21 [5.3] | 17 [81.0] | 04 [19.0] | |
Stage III | 17 [4.3] | 07 [41.2] | 10 [58.8] | |
Stage IV | 5 [1.3] | 03 [60.0] | 02 [40.0] | |
Modern non-hormonal contraceptive (n = 262) | No | 151 [57.6] | 109 [72.2] | 42 [27.8] |
Yes | 111 [42.4] | 74 [66.7] | 37 [33.3] | |
Treatment adherence | Good | 285 [72.5] | 203 [71.2] | 48 [28.8] |
Average | 30 [7.6] | 19 [63.3] | 11 [36.7] | |
Weak | 78 [19.9] | 48 [61.5] | 30 [38.5] | |
Opportunistic infections | Yes | 194 [49.4] | 132 [68.0] | 62 [32.0] |
No | 199 [50.6] | 138 [69.3] | 61 [30.7] | |
HAART regimen | 1a | 25 [6.4] | 19 [76.0] | 06 [24.0] |
1c | 152 [38.7] | 109 [71.7] | 43 [28.3] | |
1d | 52 [13.2] | 37 [71.2] | 15 [28.8] | |
1e | 122 [31.0] | 77 [63.1] | 45 [36.9] | |
1f | 42 [10.7] | 28 [66.7] | 14 [33.3] | |
Baseline CD4+ T cell counts | >  250 | 242 [61.6] | 168 [64.1] | 74 [35.9] |
≤ 250 | 151 [38.4] | 102 [67.5] | 49 [32.5] | |
Average baseline CD4+ T cell counts |  | 240 cells/μl | 258 cells/μl | |
Average current CD4+ T cell counts |  | 528 cells/μl | 414 cells/μl | |
Duration of HAART | ≤ 2 years | 59 [15.0] | 38 [64.4] | 21 [35.6] |
2–5 years | 34 [8.7] | 23 [67.6] | 11 [33.4] | |
5–10 years | 99 [25.2] | 69 [69.7] | 30 [30.3] | |
>  10 years | 201 [51.1] | 140 [69.7] | 61 [30.3] | |